Fundraising Fox
ThirtyFiveBio Limited
Oxford, GB · 3 known investors
Find your way into ThirtyFiveBio Limited
Sign up to see every warm intro you have to ThirtyFiveBio Limited
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ThirtyFiveBio Limited team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ThirtyFiveBio is a drug discovery company developing GPR35 antagonists to treat gastrointestinal diseases, with a focus on ulcerative colitis by targeting epithelial dysfunction. Founded in 2021, it operates as part of the Molecule to Medicine ecosystem and is advancing preclinical candidates toward first-in-human trials.
Founders & leadership
Investors · 3
How we know: Canaan Partners's portfolio page · the company's own site · a partner's Signal profile · prnewswire.com · Not right? Tell us
Also in the syndicate · 2
Funding
SEC filings, press & company announcementsSource: company announcements and press reports — follow each round's link for the claim.
Related companies · 2
Companies working in the same space as ThirtyFiveBio Limited.
Companies House · registry record
View on Companies House ↗- Registered name
- THIRTYFIVEBIO LIMITED
- Company number
- 13157735
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 26 Jan 2021
- Registered office
- 99 Park Drive, Milton, Abingdon, OX14 4RY
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Dec 2025 · next due 30 Sept 2027
- Confirmation statement
- last made up to 25 Jan 2026 · next due 8 Feb 2027
Current officers · 6
- Samantha Ann Harris — secretary, appointed 22 Jun 2022
- Brenton Karl Ahrens — director, appointed 13 Apr 2021
- Donmienne Doen Mun Leung — director, appointed 11 Mar 2025
- Nils Lonberg — director, appointed 28 May 2021
- Thomas David Mccarthy — director, appointed 26 Jan 2021
- James Westcott — director, appointed 29 Jun 2021
Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does ThirtyFiveBio Limited do?
- ThirtyFiveBio is a drug discovery company developing GPR35 antagonists to treat gastrointestinal diseases, with a focus on ulcerative colitis by targeting epithelial dysfunction. Founded in 2021, it operates as part of the Molecule to Medicine ecosystem and is advancing preclinical candidates toward first-in-human trials.
- Who are ThirtyFiveBio Limited's investors?
- ThirtyFiveBio Limited's investors include Canaan Partners.
- Where is ThirtyFiveBio Limited headquartered?
- ThirtyFiveBio Limited is headquartered in Oxford, GB.